chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Flatulence
Clinical narrative: Individual described feeling gassy after receiving the 2nd dose of the Pfizer Covid 19 vaccine; This is a spontaneous report from a contactable consumer. A 42-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration on an unknown date in Apr2021 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included known allergies to milk. Prior to the vaccination, the patient was not diagnosed with COVID-19. It was unknown if patient received any medications within two weeks of vaccination. It was unknown if patient received any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021, after receiving the second dose of the Pfizer COVID-19 vaccine, the patient felt gassy. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination the patient not been tested for COVID-19. The clinical outcome of the event felt gassy was recovered on unknown date of Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia
Clinical narrative: Metal taste in mouth; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EW0169) via an unspecified route of administration in the left arm on 16Apr2021 at 14:30 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. concomitant medications were not reported. The patient had no known allergies. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: ER8732) via an unspecified route of administration in the left  arm on 25Mar2021 at 13:00 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. On 17Apr2021 at 12:00, the patient experienced metal taste in mouth. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event metal taste in mouth was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Facial discomfort, Muscular weakness
Clinical narrative: Face heaviness; Hands/feet weak; Hands/feet weak; This is a spontaneous report from a contactable other healthcare professional. A 44-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 21Apr2021 at 10:15 (at the age of 44-years-old), as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. Concomitant medications included venlafaxine (MANUFACTURER UNKNOWN) and vitamin d nos (MANUFACTURER UNKNOWN); both for unspecified indication from unknown date and unknown if ongoing. The patient previously received diphenhydramine hydrochloride ( reported as BENADRYL) and pethidine hydrochloride(DEMEROL); both for unspecified indication from unknown date and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 23Apr2021, the patient experienced face heaviness and hands/feet weak. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events which included treatment with prednisone, hydroxyzine and famotidine. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events of face heaviness and hands/feet weak was recovering at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: About 9 days after first vaccine, began experiencing loud Tinnitus./ took second vaccine still have Tinnitus and it has not gotten better; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the left arm on 11Mar2021 at 08:30 (at the age of 61-year-old) and the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) via an unspecified route of administration in the left arm on 01Apr2021 (at the age of 61-year-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism. The patient had no known allergies to food, medications or other products. Concomitant medications included levothyroxine sodium (SYNTHROID) for an unspecified indication from an unknown date and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19.  The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20Mar2021, about 9 days after first vaccine, the patient began experiencing loud tinnitus. She took her second vaccine at the same location and still had tinnitus and it had not gotten better. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event loud tinnitus and still had tinnitus and not gotten better was not recovered.   No follow-up attempts are needed. No further information is expected.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Extrasystoles
Clinical narrative: Heart pulse skipping beats; This is a spontaneous report from a contactable consumer, the patient. A 75-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 21Mar2021 at 10:30 (at the age of 75-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic kidney disease stage 3, hypothyroidism and penicillin allergy. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the left arm on 24Feb2021 at 12:30 (at the age of 75-years-old) as a single dose for COVID-19 immunisation. On 14Apr2021 at 12:45, the patient experienced heart pulse skipping beats. The event resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event heart pulse skipping beats was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: Lymph node pain, Lymphadenopathy, Pain in extremity
Clinical narrative: Lymph nodes on armpit very painful and very swollen.; Lymph nodes on armpit very painful and very swollen.; Arm sore for 2 days; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 21Apr2021 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Other medical history not reported. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included sertraline hydrochloride (ZOLOFT) from an unknown date for an unknown indication and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 31Mar2021 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Apr2021, the patient experienced arm sore for 2 days, lymph nodes on armpit very painful and very swollen. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events lymph nodes on armpit very painful and very swollen was resolving at the time of this report; while that of the arm sore was recovered on 24Apr2021, after the duration of 2 days.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary pain, Peripheral swelling
Clinical narrative: Small swelling under right arm; In arm pit with soreness; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the right arm on 19Apr2021 at 11:00 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history included arthritis. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications included ibuprofen 800 (MANUFACTURER UNKNOWN), OTC ibuprofen (MANUFACTURER UNKNOWN) and ademetionine (SAM-E); all started on unknown dates and for unspecified indications. The patient had no known allergies to medications, food or other products. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 29Mar2021 at 11:00 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. On 21Apr2021 at 07:00, the patient experienced small swelling under right arm, in arm pit with soreness. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the events small swelling under right arm, in armpit with soreness were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Tinnitus; This is a spontaneous report from a non-contactable consumer, the patient. A 29-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 09Apr2021 (at the age of 29-year-old) as a single dose for COVID-19 immunisation. Medical history included shingles on an unknown date in 2013, hay fever, and acid reflux. The patient had no allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included ethinylestradiol/ferrous fumarate/norethisterone acetate (JUNEL FE), fluticasone propionate (FLONASE), and famotidine (PEPCID); all taken for an unknown indication from an unknown date and unknown if ongoing. On 09Apr2021 at 18:00, the patient experienced tinnitus. The patient's ears were ringing every few hours ever since, the first dose of the vaccine, more so the left ear than the right. It had been 2 weeks and had not stopped. The event resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event tinnitus was not recovered at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Discomfort, Tinnitus
Clinical narrative: 4 days post second Pfizer vaccine on 6/10/2021 I developed constant moderate hissing tinnitus.; I also had left side weakness where I had gotten the shot; I also had left side weakness and heaviness where I had gotten the shot; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EN8733) via an unspecified route of administration in the left arm on 06Apr2021 at 15:00 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. Medical history included polycystic ovarian syndrome. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included diphenhydramine, paracetamol, phenylpropanolamine hydrochloride (BENADRYL), ibuprofen (MANUFACTURER UNKNOWN), magnesium (MANUFACTURER UNKNOWN) and calcium, vitamin d nos (MANUFACTURER UNKNOWN),  all from unknown dates for unspecified indications and unknown if ongoing. The patient had no known allergies. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EN6208) via an unspecified route of administration in the left arm on 16Mar2021 at 15:00 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. On 10Apr2021 at 06:00, 4 days post second Pfizer vaccine on 6/10/2021, the patient developed constant moderate hissing tinnitus. She also had left side weakness and heaviness where she had gotten the shot and it still continued to 13 days later at the time of this report. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the reported events and included treatment with antihistamines and anxiety medication. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events constant hissing tinnitus, left side weakness and heaviness were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Nausea
Clinical narrative: Dizziness; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 19Apr2021 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration on 19Mar2021 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 19Apr2021, the patient experienced dizziness and nausea. The events resulted in doctor or other healthcare professional office/clinic visit. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events dizziness and nausea were not resolved at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Feeling hot, Headache, Pain
Clinical narrative: Excruciating headache; Strong body aches; Strong chills; Hot face; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: Ew0169) via an unspecified route of administration in the left arm on 22Apr2021 at 17:30 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 in Dec2020. The patient did not have any allergies to medications, food, or other products. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included levothyroxine sodium (EUTHYROX) and amlodipine (MANUFACTURER UNKNOWN); both for an unspecified indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: Ep7533) via an unspecified route of administration in the left arm on 30Mar2021 at 17:30 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. On 23Apr2021 at 06:00, the patient woke up with excruciating headache, strong body aches, strong chills and a hot face. The patient stated that no thermometer was available. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events excruciating headache, strong body aches, strong chills and hot face was not resolved at the time of reporting.  No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Rash erythematous
Clinical narrative: red rash on left side of forehead that burns; red rash on left side of forehead that burns; This is a spontaneous report from a contactable consumer, the patient. A non-pregnant female patient of unspecified age received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the right arm on 15Apr2021 as a single dose for COVID-19 immunisation. Medical history included breast cancer and allergy to sulfa and scallops. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the right arm on 25Mar2021 at 12:00 as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Apr2021 at 12:00, the patient experienced red rash on left side of forehead that burns. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of event and included treatment with antiviral med Valtrex. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event red rash on left side of forehead that burns was not resolved at the time of this report..   No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Lymph node pain, Lymphadenopathy
Clinical narrative: Fatigue day afterwards; Swollen lymph node in left armpit noticed on secondday after injection; Tender to pressure/ sore if arms reached up above head.; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) via an unspecified route of administration in the left arm on 21Apr2021 at 13:00 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history included none. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included cetirizine hydrochloride (ZYRTEC) from an unknown date for an unspecified indication. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Er8732) via an unspecified route of administration in the left arm on 31Mar2021 at 13:00 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. On 22Apr2021 the patient experienced, swollen lymph node in left armpit noticed on second day after injection. On an unknown date in Apr2021, the patient experienced tender to pressure, sore if arms reached up above head. On 23Apr2021 at 08:00, the patient experienced fatigue day afterwards. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fatigue day afterwards, swollen lymph node in left armpit noticed on second day after injection. Tender to pressure, sore if arms reached up above head was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Muscle twitching
Clinical narrative: twitch in muscle on left cheek of face; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the right arm on 29Mar2021 at 14:00 (at the age of 50-years-old) and received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the right arm on 19Apr2021 at 14:00 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included congestive heart failure (CHF), oxygen saturation low, CPAP (continuous positive airway pressure) and penicillin allergy. The patient took other unspecified medications within two weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On unknown date in Mar2021, the patient had a twitch in muscle on left cheek of face. It did it for a couple days after first shot then went away. On 19Apr2021, after second shot it seemed to worsen and had not gone away. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of adverse event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event twitch in muscle on left cheek of face (onset date: Mar2021) was resolved on unknown date in 2021 and event twitch in muscle on left cheek of face (onset date: 19Apr2021) was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Severe tinnitus in left ear; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 08Apr2021 at 17:30 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were reported as "na" (not applicable). The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 09Apr2021 at 23:30, 30 hours after the first shot in the left arm the patient started suffering from severe tinnitus in the left ear. The patient reported that it was still ongoing 14 days after it started (at the time of this report). At the time of this report, the patient was contemplating not to take the second dose or only when the symptoms improved. The event resulted in doctor or other healthcare professional office/clinic visit. The patient saw an ENT (ear, nose and throat) doctor. Therapeutic measures were taken as a result of the event and included treatment with unspecified steroids but without result. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event severe tinnitus in left ear was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Chills, Dizziness, Fatigue, Headache
Clinical narrative: Intense chills; Dizziness; Muscle soreness; Abdominal cramps; Lower back cramps; Headache; Fatigue; Nausea; This is a spontaneous report from a non-contactable consumer, the patient. A 32-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 16Apr2021 at 12:00 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient did not take any concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 26Mar2021 at 12:00 as a single dose for COVID-19 immunisation. On 16Apr2021 at 21:00, the patient experienced intense chills, dizziness, muscle soreness, abdominal cramps, lower back cramps, headache, fatigue and nausea. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events intense chills, dizziness, muscle soreness, abdominal cramps, lower back cramps, headache, fatigue and nausea was recovered on an unknown date in Apr2021.  No follow-up attempts are possible. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Muscle spasms, Myalgia, Nausea
Clinical narrative: Intense chills; Dizziness; Muscle soreness; Abdominal cramps; Lower back cramps; Headache; Fatigue; Nausea; This is a spontaneous report from a non-contactable consumer, the patient. A 32-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 16Apr2021 at 12:00 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient did not take any concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 26Mar2021 at 12:00 as a single dose for COVID-19 immunisation. On 16Apr2021 at 21:00, the patient experienced intense chills, dizziness, muscle soreness, abdominal cramps, lower back cramps, headache, fatigue and nausea. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events intense chills, dizziness, muscle soreness, abdominal cramps, lower back cramps, headache, fatigue and nausea was recovered on an unknown date in Apr2021.  No follow-up attempts are possible. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Dizziness, Fatigue, Feeling abnormal
Clinical narrative: Began to feel dizzy or lightheaded; Spacey and weak; Spacey and weak; Tired; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8731) via an unspecified route of administration in the left arm on 23Apr2021 at 10:30 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to sulfa antibiotics. Concomitant medications included pravastatin (MANUFACTURER UNKNOWN) and melatonin (MANUFACTURER UNKNOWN); both taken for unknown indications from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received moxifloxacin hydrochloride (AVELOX) taken for unknown indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 23Apr2021 at 16:00, approximately 5.5 hours after receiving the vaccine, the patient began to feel dizzy or lightheaded, or spacey and weak. This lasted for 5-10 minutes, then the patient was tired for the rest of the evening. Although it was not major, the patient thought it was best to report. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events began to feel dizzy or lightheaded and spacey and weak were recovered on 23Apr2021 while the event tired was recovered on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Feeling abnormal, Headache, Influenza like illness, Pain
Clinical narrative: Started with pain in arm of injection site moved throughout whole body; Brain fog; Felt like flu; Headache; Light headed; Feverish; Started with pain in arm of injection site.; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 19Apr2021 at 10:00 (at the age of 54-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. The patient did not take any concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 29Mar2021 at 10:00 (at the age of 54-year-old) as a single dose for COVID-19 immunisation. On 19Apr2021 at 20:00, the patient experienced pain in arm of injection site, moved throughout whole body and felt like flu. It had been 5 days since the 2nd shot and the patient was still feverish and had headache, was light headed, and what google described as brain fog. It appeared to be diminishing slowly but the patient still felt it. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care.  Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events started with pain in arm of injection site, started with pain in arm of injection site moved throughout whole body, felt like flu, feverish, headache, light headed, and brain fog were resolving at the time of the report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia, Vaccination site pain
Clinical narrative: Started with pain in arm of injection site moved throughout whole body; Brain fog; Felt like flu; Headache; Light headed; Feverish; Started with pain in arm of injection site.; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 19Apr2021 at 10:00 (at the age of 54-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. The patient did not take any concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 29Mar2021 at 10:00 (at the age of 54-year-old) as a single dose for COVID-19 immunisation. On 19Apr2021 at 20:00, the patient experienced pain in arm of injection site, moved throughout whole body and felt like flu. It had been 5 days since the 2nd shot and the patient was still feverish and had headache, was light headed, and what google described as brain fog. It appeared to be diminishing slowly but the patient still felt it. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care.  Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events started with pain in arm of injection site, started with pain in arm of injection site moved throughout whole body, felt like flu, feverish, headache, light headed, and brain fog were resolving at the time of the report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Lactose intolerance
Clinical narrative: Lactose intolerance.; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6200) via an unspecified route of administration in the left arm on 30Mar2021 at 10:30 (at the age of 68-years-old), as a single dose for COVID-19 immunisation. Medical history included allergy to penicillin (PCN) and sulfa. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included tamsulosin 4mg (MANUFACTURER UNKNOWN), finasteride 5mg (MANUFACTURER UNKNOWN) and duloxetine 30mg (MANUFACTURER UNKNOWN); all for unspecified indication from unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6200) via an unspecified route of administration in the left arm on 09Mar2021 (at the age of 68-years-old), as a single dose for COVID-19 immunisation. On 04Apr2021 at 05:30, the patient experienced lactose intolerance. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event lactose intolerance was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pruritus, Vaccination site swelling
Clinical narrative: Having swelling at the injection site; Major itch at the injection site; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the right arm on 20Apr2021 at 21:15 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant past medical history. The patient had no known allergies to medications, food or other products. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the right arm on 09Mar2021 at 02:15 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Apr2021 at 06:30, the patient had swelling at the injection site and major itch. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events having swelling at the injection site and major itch at the injection site were unknown at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Impaired driving ability, Impaired work ability, Insomnia, Myalgia
Clinical narrative: Worsening muscle and joint aches; Worsening muscle and joint aches; Too uncomfortable to sleep, work, drive etc; Too uncomfortable to sleep, work, drive etc; Too uncomfortable to sleep, work, drive etc; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0151) via an unspecified route of administration in the left arm on 23Apr2021 at 10:00 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to epoxy. The patient received unspecified oral contraceptives within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8737) via an unspecified route of administration in the left arm on 02Apr2021 at 10:00 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 24Apr2021 at 04:00, the patient experienced worsening muscle and joint aches in the day after the shot and the patient felt too uncomfortable to sleep, work, drive, etc. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination the patient had not been tested for COVID-19. The clinical outcome of the events worsening muscle and joint aches and the event too uncomfortable to sleep, work, drive etc were unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Insomnia
Clinical narrative: Had insomnia a day after my vaccination and got no more than 1 hour sleep over the course of the night. It was wide awake and unable to fall asleep. It wasnt jittery, and couldn't fall asleep.; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: Ew0171) via an unspecified route of administration in the right  arm on 22Apr2021 at 16:30 (at the age of 42-year-old) as a single dose for COVID-19 immunisation. Medical history included sulfonamide allergy. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included liraglutide (SAXENDA), bupropion (MANUFACTURER UNKNOWN) and multivitamins (MANUFACTURER UNKNOWN) all from unknown indication on an unknown date and unknown if ongoing. The patient previously received sulfamethoxazole, trimethoprim (BACTRIN) for unknown indication on unknown date and experienced drug allergy. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: Er8732) via an unspecified route of administration in the left arm on 23Mar2021 at 11:30 (at the age of 42-year-old) as a single dose for COVID-19 immunisation. On 23Apr2021 at 22:30, after receiving the vaccine next day night, the patient experienced insomnia and got no more than 1 hour sleep over the course of the night. she was wide awake and unable to fall asleep. she wasn't jittery, and she could quiet her mind, but just couldn't fall asleep. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event insomnia was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: Steady headache in the front of forehead; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 09Apr2021 at 09:15 (at the age of 35-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medication included citalopram (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 17Mar2021 at 10:30 (at the age of 35-year-old) as a single dose for COVID-19 immunisation.  On 09Apr2021 at 12:00, the patient experienced steady headache in the front of forehead, not all day, but it was pretty much every day for a few hours. It was also reported that the patient was never been the one who suffered from headaches. The adverse event did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the reported event. The clinical outcome of the event steady headache in the front of forehead was not resolved at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspepsia
Clinical narrative: Heartburn started a few minutes after my shot but was mild.  Went away after a couple hours.  Then came back really bad; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) via an unspecified route of administration in the left arm on 20Apr2021 at 09:15 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included ibuprofen (ADVIL), gabapentin (MANUFACTURER UNKNOWN), duloxetine (MANUFACTURER UNKNOWN), cetirizine hydrochloride (ZYRTEC) and norethisterone (MANUFACTURER UNKNOWN); all from an unknown date for an unknown indication. The patient previously took ketorolac tromethamine (TORADOL) and cephalexin (MANUFACTURER UNKNOWN) and experienced drug allergy. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 29Mar2021 at 00:15 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. On 20Apr2021 at 09:15, the patient experienced heartburn started a few minutes after her shot but was mild.  Went away after a couple hours. Then came back really bad around 20:30. She never got heartburn and had not eaten anything unusual to cause it. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of heartburn and included treatment with pepcid, baking soda water and ginger. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event heartburn was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Left arm (injection site) burning sensation; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 02Apr2021 at 11:30 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Medical history included high cholesterol, blood pressure high and seafood allergy (Shrimp). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications were not reported. On 03Apr2021 around 09:30, the patient experienced left arm (injection site) burning sensation for about an hour or two. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event left arm (injection site) burning sensation recovered on 03Apr2021.  No follow-up attempts are needed. No further information is expected.